MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (OTCBB: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced that it has withdrawn its previously announced public offering of 10,000,000 shares of common stock under its shelf registration statement given current market conditions.
About Ocata Therapeutics, Inc.
Ocata Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of novel therapies based on terminally differentiated cells.
Contacts
Investors:
Westwicke Partners
John Woolford, 443-213-0506
john.woolford@westwicke.com
Help employers find you! Check out all the jobs and post your resume.
About Ocata Therapeutics, Inc.
Ocata Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of novel therapies based on terminally differentiated cells.
Contacts
Investors:
Westwicke Partners
John Woolford, 443-213-0506
john.woolford@westwicke.com
Help employers find you! Check out all the jobs and post your resume.
